Broadfin Capital, LLC, 10% Owner at Recro Pharma, Inc. (REPH), sold 188,000 shares at $6.00 ($1.1M) on 2018-05-24, disclosed to the SEC on 2018-05-24.
Open-market sale of $1.1M REPH by 10% Owner. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $5.51 | 25,000 | $138K | 12.6% |
| 2 | $5.65 | 50,000 | $283K | 25.8% |
| 3 | $5.84 | 29,300 | $171K | 15.7% |
| 4 | $5.99 | 38,000 | $228K | 20.8% |
| 5 | $6.00 | 45,700 | $274K | 25.1% |
| Total | $5.81 avg | 188,000 |
| $1.1M |
| 100% |
| Filing → |
| BDSI | SELL | 2019-05-14 | $9.0M | — | Filing → |
| REPH | SELL | 2018-03-15 | $2.0M | — | Filing → |
| PETX | SELL | 2017-12-01 | $2.6M | — | Filing → |